Alkermes (ALKS) EBITDA (2010 - 2026)

Alkermes (ALKS) has 17 years of EBITDA data on file, last reported at -$67.3 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$67.3 million, down 392.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $151.3 million (down 57.37% YoY), and the FY2025 annual result was $241.5 million, down 34.4% from the prior year.
• EBITDA slipped to -$67.3 million in Q1 2026 per ALKS's latest filing, from $48.3 million in the prior quarter.
• Over five years, EBITDA peaked at $237.8 million in Q2 2023 and troughed at -$67.3 million in Q1 2026.
• A 5-year average of $43.6 million and a median of $48.3 million in 2025 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2023: EBITDA slumped 6840.9% in 2022, then surged 834.04% in 2023.
• A 5-year view of EBITDA shows it stood at -$26.3 million in 2022, then soared by 539.99% to $115.7 million in 2023, then rose by 24.51% to $144.1 million in 2024, then plunged by 66.48% to $48.3 million in 2025, then slumped by 239.31% to -$67.3 million in 2026.
• Business Quant data shows ALKS's EBITDA at -$67.3 million in Q1 2026, $48.3 million in Q4 2025, and $83.1 million in Q3 2025.